The SURPASS-CVOT trial (ClinTrials.gov registration no
And all of a sudden, her motility came back
The most common gastrointestinal side effects include: Nausea : Reported in 15-44% of patients (higher rates at Wegovy 2.4 mg), typically most pronounced during dose escalation Diarrhea : Affects approximately 8-30% of users, ranging from mild to moderate severity Vomiting : Occurs in 5-24% of patients (higher rates at Wegovy 2.4 mg), often associated with rapid dose increases Abdominal pain : Experienced by 5-20% of patients, usually described as cramping or discomfort Constipation : Paradoxically affects 3-24% despite the medication's effects on motility Dyspepsia and gastroesophageal reflux : Related to delayed gastric emptying These effects result from semaglutide's pharmacologic action on GLP-1 receptors throughout the gastrointestinal tract
Tirzepatide is a dual agonist that targets glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)
Bikman explains tirzepatide, the dual-incretin drug that activates both GLP-1 and GIP receptors
Valenzuela-Vallejo L, Guatibonza-Garcia V, Mantzoros CS